UK/Medicon Valley Drug Development Seminar & Partnering Event
3 March 2005 / 8:30 - 17:00 / British Embassy / Denmark
Drug Development is a complicated and highly regulated process. The increasing cost of getting a drug to market means that companies have to consider each stage of the development pathway seriously. Fast and effective development of new drugs is essential in order to gain maximum value within the products patent life. This seminar aims to explore each stage of the development of a drug, from pre-clinical through GMP manufacture to clinical trials.
BioNow, Medicon Valley Alliance and UKTI at the British Embassy have arranged for a delegation of prestigious UK organisations to meet with their Danish counterparts at a seminar at the British Embassy, Copenhagen on 3 March 2005.
The seminar offers a two-way dialogue on leading-edge drug development. Targeted presentations followed by business partnering meetings with UK specialists and exclusive networking sessions will create privileged opportunities for future co-operation between Scandinavian and UK organisations.
Take this opportunity to meet the key UK players and network with some of the most prestigious UK and DK organisations within drug development i.e. Celltech, Eden BioDesign, Quay Pharmaceuticals, Epistem, Trial Form Support, SAFC etc.
Please confirm your presence by Monday 21 February to: ilana.rawlings@fco.gov.uk or phone: +45 35 44 52 76.
To book a direct meeting with the specialists involved, please tick the box of the person you would like to meet in the attached form (pdf) and return it to the British Embassy by fax or e-mail.
AGENDA
08:30 Registration, breakfast & coffee
09:00 Welcome by HMA
09:10 Welcome by MVA
09:20 Event Introduction
Mr. Philip Oliver, International Technology Promoter, Life Sciences, Europe
09:30 Pre-Clinical Drug Development
Dr Ceri Batchelder, Business Development Manager, Epistem Ltd
09:45 Early Stage ADME Prediction
Dr Robert Atwater, Chairman/CEO, Cyprotex plc
10:00 Lead Optimisation
Mr. Per Spindler
10:15 Non-Clinical Toxicology
Dr Robert Harling, Scientific Director, Scantox
10:30 Coffee Break
10:45 Biologics Manufacturing and the UK National Biomanufacturing Centre
Dr Crawford Brown, CEO, Eden BioDesign
11:15 Issues around Small-scale Pharmaceutical Manufacturing
Dr Michael Harris, Head of Business Development, SAFC Ltd
11:45 Fill-Finish for Bio/pharma products
Mr. Mark Quick, Head of Business Development, UCB-Celltech Manufacturing Services
12:00 Lunch
13:00 New Safe Medicines Faster
Dr Jørgen Dirach, Novo Nordisk
13:30 Drug Formulation to improve availability and efficacy
Prof. Mike Rubinstein, CEO Quay Pharmaceuticals
14:00 Mr. Niklas Lindberg, Dir. Clinical Operations, Trial Form Support, Sweden (presentation title to be confirmed)
14:15 Early Clinical Trials in Medicon Valley - PhaseOne Trials Experience
Dr Kim Krogsgaard, PhaseOne Trials
14:30 UK Clinical Trials
Mr. Keith Chantler, Associate R&D Director, Central Manchester NHS Trust and Director TrusTECH
14:45 Closing remarks/discussion
15:00 Business partnering
17:00 End
More information (pdf)